You are here
It is unknown if inhibiting cholesterol synthesis (with statins) might influence sex-hormone production and therefore, the risk of osteoporosis. A new study shows that, in statin-treated individuals, the development of osteoporosis is statin dose-dependent.
This Austrian, claims based study (2006 to 2007) examined the association between statin therapy and OP risk.
The found that in the general population, statin use was associated with a 3 fold higher rate of osteoporosis (OR: 3.62, 95% CI 3.55 to 3.69, p<0.01).
Osteoporosis was significantly lower with low-dose (< 10 mg) statin treatment (e.g., lovastatin [OR: 0.39], pravastatin [OR: 0.68], simvastatin [OR: 0.70] and rosuvastatin [OR: 0.69]; p<0.01).
In contrast, higher doses significantly increased the odds of OP (> 40 mg simvastatin [OR: 1.64]; >20 mg atorvastatin [OR: 1.78]; >20 mg rosuvastatin [OR: 2.04].
It appears that the risk of OP is largely dose-dependent as regards statin use.